What if the fate of a new drug is decided in a single public meeting?
It happens.
FDA advisory committee panels are often the moment the agency leans on outside experts before a final approval.
Their calendar is where you’ll find upcoming panels, PDUFA (Prescription Drug User Fee Act) target dates, briefing books, webcasts, and public comment dockets.
This guide shows how to read the FDA advisory committee meetings calendar, spot the dates and documents that matter, and track the signals that predict approval outcomes.
FDA Advisory Committee Meeting Calendar Overview
The FDA keeps a live advisory committee meeting calendar that tracks every scheduled panel session where external experts review drug and biologic applications. These meetings are decision points. Experts dig into evidence packages, discuss safety and efficacy data, and vote on whether a therapy should get approval.
Right now, the FDA calendar shows several active and upcoming PDUFA target action dates and advisory assignments running from January through February 2026:
February 25, 2026 – ETON Pharmaceuticals (ETON): ET-600 (desmopressin oral solution) for central diabetes insipidus hits its PDUFA target action date. The FDA accepted the NDA for ET-600 after clinical trials wrapped. The specific advisory committee hasn’t been disclosed publicly, though central diabetes insipidus therapies usually go to endocrinology or metabolic disorders panels.
February 28, 2026 – Ascendis Pharma (ASND): TransCon CNP (navepegritide) for children with achondroplasia reaches its PDUFA decision date. Ascendis announced the FDA extended the review period for TransCon CNP, pushing back the original target. Achondroplasia is a rare genetic bone growth disorder. Pediatric advisory panels or bone/reproductive/urologic drug committees often review therapies for pediatric skeletal conditions.
February 28, 2026 – BioMarin Pharmaceutical (BMRN): PALYNZIQ (pegvaliase-pqpz) supplemental Biologics License Application (sBLA) for phenylketonuria reaches its PDUFA decision date. The FDA accepted BioMarin’s PALYNZIQ sBLA for priority review to expand approved use to adolescents aged 12–17. The original BLA covered adult patients. This supplemental filing seeks to broaden the age indication. Metabolic or endocrine advisory committees typically handle phenylketonuria therapies.
Each advisory committee meeting follows a structured format. The FDA posts meeting pages that include the committee name and type (for example, ODAC reviews cancer therapies, VRBPAC reviews vaccines), the exact meeting date and start time, a published agenda outlining topics and voting questions, and briefing documents prepared by both the FDA and the sponsor.
Briefing documents (often called the “briefing book”) contain detailed background on the drug candidate, clinical trial data summaries, FDA staff analyses, and specific questions the agency wants the committee to address. These documents typically drop one to two days before the meeting, giving stakeholders time to review the evidence before the panel convenes.
The FDA also provides instructions for public participation. Open comment periods let patients, clinicians, and advocacy groups present testimony during the meeting. Written comments can be submitted to the public docket before and after the meeting. Most advisory committee sessions are webcast live, and archived video and audio recordings stay accessible on the FDA website after the meeting wraps.
Advisory committee schedules change. The FDA may reschedule meetings due to data updates, sponsor requests, or agency workload. Extensions to PDUFA target action dates happen when additional time is needed for review or when sponsors submit major amendments to their applications. If you’re tracking specific drug approvals, verify meeting dates, committee assignments, and briefing document availability directly through the FDA’s official advisory committee calendar and the sponsor’s press releases.
For the February 2026 PDUFA dates listed above, official advisory committee assignments, meeting start times, panel membership lists, explicit voting questions, and voting outcomes weren’t specified in available sources at the time of this report. These details appear on the meeting page and in post-meeting transcripts and minutes once published by the FDA.
How FDA Advisory Committees Function
FDA advisory committees are independent expert panels that review scientific evidence and provide non-binding recommendations to the agency. The FDA convenes these committees when a drug application presents novel scientific questions, addresses rare diseases with limited historical data, involves new therapeutic classes, or raises complex safety or efficacy concerns that benefit from external expert input.
Committee composition varies by therapeutic area but typically includes clinical specialists (oncologists, cardiologists, infectious disease experts), biostatisticians, clinical pharmacologists, patient representatives, and occasionally consumer or industry liaison members. Most committees have 10 to 15 voting members, plus a non-voting industry representative and a non-voting patient or consumer representative. Members are vetted for conflicts of interest. Those with financial ties to the sponsor or competing companies may be recused from voting or excluded from the meeting entirely.
Each advisory committee meeting follows a standard agenda structure. The sponsor presents clinical trial results, including efficacy data, safety profiles, dosing rationale, and proposed labeling. The FDA then presents its own analysis, which may highlight data gaps, statistical concerns, or safety signals that differ from the sponsor’s interpretation. After presentations, the committee discusses the evidence in an open forum. This discussion is critical. Committee members raise questions, debate endpoints, assess benefit-risk balance, and explore alternative interpretations of trial data.
Following discussion, the committee moves to a formal vote. Voting questions are framed by the FDA and typically ask whether the data support approval, whether additional studies are needed, or whether specific safety restrictions should apply. Committee members vote yes, no, or abstain, and each member explains their vote on the record. Vote tallies are public, and dissenting opinions are documented.
Advisory committee recommendations aren’t binding. The FDA considers the committee’s vote and discussion as one input among many. The agency also weighs public comments, post-marketing surveillance data, regulatory precedent, and internal staff reviews. The FDA may approve a drug even after a negative committee vote, or issue a Complete Response Letter (CRL) after a positive vote, though such outcomes are less common.
Committee meetings also include an open public hearing segment. During this time, patients, caregivers, clinicians, and advocacy organizations present testimony. Public testimony often focuses on unmet medical need, quality of life impacts, and real-world treatment burdens that clinical trial data may not fully capture. This testimony provides context that can influence both the committee’s perspective and the FDA’s final decision.
After the meeting, the FDA reviews the full record: presentations, committee discussion, vote rationale, and public comments. That decision arrives on or before the PDUFA target action date, which is set according to the Prescription Drug User Fee Act timelines: up to 10 months for standard review or up to 6 months for priority review.
Accessing Webcasts, Dockets, and Meeting Materials
Most FDA advisory committee meetings are broadcast live via webcast, and the FDA archives video and audio recordings on the official advisory committee meeting pages. No registration is required to view live or archived webcasts. You can access the webcast link directly from the meeting page listed on the FDA’s advisory committee calendar.
Briefing documents are the primary materials reviewed by committee members and drop one to two days before the scheduled meeting. These documents include the sponsor’s briefing book, the FDA’s review memo, and statistical analyses. The sponsor’s briefing book summarizes clinical trial design, patient demographics, efficacy results, adverse event profiles, and proposed labeling. The FDA’s review memo presents the agency’s independent analysis, often including additional safety assessments, statistical re-analyses, and a preliminary benefit-risk evaluation.
To locate briefing documents for a specific meeting, navigate to the advisory committee calendar, select the meeting date, and open the meeting page. Briefing documents are posted as PDF files under a “Meeting Materials” or “Briefing Documents” heading. Some meetings also include slide presentations used during the session.
Public dockets are another key resource. Each advisory committee meeting has a docket number, which serves as the official repository for public comments submitted before, during, and after the meeting. Dockets remain open for a defined period, typically 30 days after the meeting. To submit a comment, search for the docket number on the FDA’s public docket portal (the Federal Docket Management System), locate the meeting docket, and upload a written comment or attach supporting documents. All submitted comments become part of the public record and are reviewed by FDA staff.
The FDA also publishes meeting transcripts and minutes after advisory committee sessions conclude. Transcripts capture the full verbal record, including presentations, committee discussion, public testimony, and vote explanations. Minutes provide a condensed summary of key discussion points and the final vote tally. Both documents are posted on the meeting page, usually within several weeks of the meeting date.
For users tracking a specific drug candidate, setting up alerts for docket updates and checking the advisory committee calendar weekly ensures timely access to new briefing documents, schedule changes, and vote outcomes. The FDA occasionally updates meeting times or postpones sessions, so verifying details on the official calendar before the meeting date is essential.
Archived webcasts and transcripts are valuable for understanding how the FDA and advisory committees evaluate specific evidence types (such as surrogate endpoints, single-arm trials, or accelerated-approval pathways) and provide historical context for interpreting future meetings in similar therapeutic areas.
Understanding Outcomes and What Happens After a Meeting
Advisory committee votes provide guidance to the FDA but don’t determine the final approval decision. A positive committee vote (where the majority of voting members support approval) signals that external experts believe the evidence supports the drug’s benefit-risk profile. However, the FDA retains full authority to approve, reject, or request additional data regardless of the committee’s recommendation.
After the meeting, the FDA reviews the complete record: the committee’s vote and rationale, the full discussion transcript, public testimony, written docket comments, and internal staff analyses. The agency also considers any new information submitted by the sponsor after the meeting, such as updated safety data or responses to committee questions.
The PDUFA target action date marks the deadline by which the FDA commits to issuing a regulatory decision. For standard review applications, this date falls up to 10 months after the FDA accepts the application. For priority review applications, the timeline shortens to up to 6 months. If the sponsor submits a major amendment (such as new clinical data or a revised manufacturing process), the FDA may extend the PDUFA date by up to three months.
Three primary outcomes are possible on the PDUFA action date:
Approval – The FDA issues an approval letter, allowing the sponsor to market the drug. Approval may include post-marketing requirements (PMRs) or post-marketing commitments (PMCs) that obligate the sponsor to conduct additional studies, such as pediatric trials, long-term safety studies, or confirmatory efficacy trials under an accelerated-approval pathway.
Complete Response Letter (CRL) – The FDA issues a CRL when the application doesn’t meet approval standards. The CRL outlines deficiencies, which may include insufficient efficacy evidence, unresolved safety concerns, manufacturing quality issues, or inadequate risk-mitigation plans. Sponsors can address the deficiencies and resubmit the application. Resubmissions trigger a new PDUFA review cycle, either a two-month or a six-month timeline, depending on the extent of the changes.
Review Extension – The FDA may extend the review period if it needs additional time to evaluate complex data or if the sponsor submits a major amendment. Extensions are announced publicly, and a new PDUFA target date is assigned.
Advisory committee voting patterns offer insight into the FDA’s likely decision, but exceptions occur. The FDA has approved drugs after narrow or split votes, and has issued CRLs after unanimous positive votes when post-meeting data raised new concerns. Negative votes (especially unanimous ones) strongly correlate with CRLs, but the FDA has occasionally approved drugs with narrow negative votes when the agency’s internal analysis supported approval.
After approval, the FDA continues to monitor the drug through post-marketing surveillance systems, including adverse-event reports submitted to the FDA’s MedWatch program and data from the Sentinel Initiative, which tracks real-world safety signals. If serious safety issues emerge, the FDA may require label updates, restrict the approved indication, or in rare cases, withdraw approval.
How to Find Past FDA Advisory Committee Meetings
The FDA maintains a public archive of past advisory committee meetings, accessible through the advisory committee meeting pages on the FDA website. This archive includes meeting dates, committee names, drug names, voting outcomes, briefing documents, transcripts, and archived webcasts.
To search past meetings, navigate to the FDA’s advisory committee calendar page and filter by committee type, therapeutic area, or date range. Each committee has its own landing page listing all historical meetings. For example, the Oncologic Drugs Advisory Committee (ODAC) page lists every ODAC meeting since the committee’s inception, with links to individual meeting pages.
Each archived meeting page includes:
Meeting materials – Sponsor and FDA briefing documents, slide presentations, and background materials.
Transcripts – Full verbatim records of presentations, committee discussion, public testimony, and vote explanations.
Vote outcomes – Final vote tallies and individual member votes, including explanations for yes, no, and abstain votes.
Archived webcasts – Video and audio recordings of the full meeting.
Docket comments – Public comments submitted before and after the meeting.
Archived meetings are valuable for understanding how the FDA and advisory committees evaluate specific types of evidence. Reviewing past meetings on accelerated-approval pathways or single-arm trials provides insight into the level of evidence the FDA considers sufficient for approval in rare diseases or high-unmet-need conditions.
Historical meeting data also reveals trends in committee voting behavior. Some committees have a higher threshold for approval, while others are more receptive to novel endpoints or real-world evidence. Tracking voting patterns over time helps predict likely outcomes for upcoming meetings in similar therapeutic areas.
To locate a specific past meeting, use the drug name or sponsor name as a search term on the committee’s landing page. The FDA’s site search function also indexes meeting transcripts and briefing documents, allowing keyword searches across all archived materials.
For researchers and investors analyzing drug-approval trends, the archived meetings provide a dataset for evaluating factors that influence approval decisions: trial design, endpoint selection, safety signal management, and the role of patient testimony in swaying committee opinion.
Final Words
You’ve got the up-to-date calendar, how committees work, where to watch webcasts, and how outcomes play out.
This guide showed what each meeting includes, how to read votes, and where to find past archives — all so you can track milestones without digging.
Use the FDA advisory committee meetings calendar for drug approvals as your quick reference for upcoming decisions. Stay tuned to official postings for schedule changes, and you’ll be better prepared when agencies weigh in.
FAQ
Q: How often should advisory committees meet?
A: Advisory committees should meet as needed; frequency varies by committee and workload—many convene several times a year, while others meet only for specific product reviews or emerging safety issues.
Q: What is the timeline for FDA Type A meeting?
A: The timeline for an FDA Type A meeting is a target of 30 calendar days from request; it addresses stalled development or clinical holds, with FDA follow-up usually provided in writing about 30 days after the meeting.
Q: Do FDA advisory committee members get paid?
A: FDA advisory committee members are generally unpaid for meeting service; FDA typically reimburses travel, lodging, and per diem, and certain experts designated as special government employees may receive limited compensation under agency rules.
Q: What is the PDUFA calendar?
A: The PDUFA calendar is a schedule of FDA target action dates for prescription drug and biologic reviews under the Prescription Drug User Fee Act, showing expected decision deadlines and review types (standard vs priority).